Nepal retrospective study characterizes 51 ALK- or ROS1-positive tumors
A Nepal single-centre retrospective study characterized 51 ALK- or ROS1-positive cases, including 49 non-small cell lung cancers and two inflammatory ...
Tag: lorlatinib
Rare ALK Fusion Lung Cancer Shows Durable Response to First-Line Lorlatinib
A newly reported case shows that first-line lorlatinib achieved durable systemic and intracranial disease control in a patient with the ...
New Molecular Glue Degrader TRI-611 Eliminates ALK-Driven Lung Cancer, Including in the Brain
Scientists report that TRI-611, a brain-penetrant molecular glue degrader, eliminates ALK fusion proteins and drives tumor regressions in preclinical models ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!